Share This Article:

A Case of Advanced Multiple Hepatocellular Carcinomas with Portal Vein Tumor Thrombosis Successfully Treated by Oral Tegafur/Uracil

Abstract Full-Text HTML Download Download as PDF (Size:1409KB) PP. 160-164
DOI: 10.4236/jct.2010.13025    3,771 Downloads   7,468 Views  

ABSTRACT

A case of advanced multiple hepatocellular carcinomas (HCC) with portal vein tumor thrombosis successfully treated by oral tegafur/uracil is reported. A 69-year-old Japanese woman with advanced HCC with tumor thrombosis underwent transcatheter arterial infusion chemotherapy in April 2001. However, 1 year later, the patient experieced a recurrence with advanced multiple HCC with portal vein tumor thrombosis and ascites. Treatment with oral tegafur/uracil was started in May 2002 and resulted in the partial response of liver tumors and the complete improvement of ascites. She remained in good health for about 6 years. This case strongly suggests that oral tegafur/uracil is an effective treatment for some cases of advanced HCC with portal vein tumor thrombosis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

H. Tanaka, H. Koga, M. Hasegawa, H. Takihara, E. Kimura, T. Inoue, C. Ueda, W. Ono, S. Takamatsu, Y. Nakamura and H. Ueda, "A Case of Advanced Multiple Hepatocellular Carcinomas with Portal Vein Tumor Thrombosis Successfully Treated by Oral Tegafur/Uracil," Journal of Cancer Therapy, Vol. 1 No. 3, 2010, pp. 160-164. doi: 10.4236/jct.2010.13025.

References

[1] J. Bruix, J. M. Llovet, A. Castells, X. Montana, C. Bru, M. C. Ayuso, R. Vilana and J. Rodes, “Transarterial Embolization Versus Symptomatic Treatment in Patients with Advanced Hepatocellular Carcinoma: Results of a Randomized, Controlled Trial in a Single Institution,” Hepatology, Vol. 27, No. 6, 1998, pp. 15781583.
[2] J. M. Llovet, M. I. Real, X. Montana, R. Planas, S. Coll, J. Aponte, C. Ayuso and M. Sala, “Arterial Embolization or Chemoembolization Versus Symptomatic Treatment in Patients with Unresectable Hepatocellular Carcinoma: A Randomized Controlled Trial,” Lancet, Vol. 359, No. 9319, 2002, pp. 17341739.
[3] T. Livraghi, V. Benedini, S. Lazzaroni, F. Meloni, G. Torzilli and C. Vettori, “Long Term Results of Single Session Percutaneous Ethanol Injection in Patients with Large Hepatocellular Carcinoma,” Cancer, Vol. 83, No. 1, 1998, pp. 4857.
[4] R. Tateishi, S. Shiina, T. Teratani, S. Obi, S. Sato, Y. Koike, T. Fujishima, H. Yoshida, T. Kawabe and M. Omata, “Percutaneous Radiofrequency Ablation for He patocellular Carcinoma: An Analysis of 1000 Cases,” Cancer, Vol. 103, No. 6, 2005, pp. 12011209.
[5] T. Yamamoto, H. Nagano, Y. Imai, K. Fukuda, H. Matsumoto, M. Kondo, H. Ota, M. Nakamura, H. Wada, T. Noda, B. Damdinsuren, K. Dono, K. Umeshita, S. Nakamori, M. Sakon, K. Wakasa and M. Monden, “Successful Treatment of Multiple Hepatocellular Carcinoma with Tumor Thrombi in the Major Portal Branches by Intraarterial 5Fluorouracil Perfusion Chemotherapy Combined with Subcutaneous InterferonAlpha and Hepatectomy,” International Journal of Clinical Oncology, Vol. 12, No. 2, 2007, pp. 150154.
[6] M. Sakon, H. Nagano, K. Dono, S. Nakamori, K. Ume shita, A. Yamada, S. Kawata, Y. Imai, S. Iijima and M. Monden, “Combined Intraarterial 5Fluorouracil and Subcutaneous InterferonAlpha Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombi in the Major Portal Branches,” Cancer, Vol. 94, No. 2, 2002, pp. 435442.
[7] M. Akamatsu, H. Yoshida, S. Obi, S. Sato, Y. Koike, T. Fujishima, R. Tateishi, M. Imamura, K. Hamamura, T. Teratani, S. Shiina, T. Ishikawa and M. Omata, “Evaluation of Transcatheter Arterial Embolization Proir to Per cutaneous Tumor Ablation in Patients with Hepa tocellular Carcinoma: A Randomized Controlled Trial,” Liver International, Vol. 24, No. 6, 2004, pp. 625629.
[8] K. Ohmoto, N. Yoshioka, Y. Tomiyama, N. Shibata, T. Kawase, K. Yoshida, M. Kuboki and S. Yamamoto, “Comparison of Therapeutic Effects between Radiofre quency Ablation and Percutaneous Microwave Coa gulation Therapy for Small Hepatocellular Carcinomas,” Journal of Gastroenterology and Hepatology, Vol. 24, No. 2, 2008, pp. 223227.
[9] J. Felieu, M. Gonzalez Baron, E. Espinosa, C. Garcia Giron, I. de la Gandara, J. Espinosa, A. Colmenarejo, J. I. Jalon, Y. Femandez and J. de Castro, “Uracil and Tegafur Modulated with Leucovorin; an Effective Regimen with Low Toxicity for the Treatment of Colorectal Carcinoma in the Elderly,” Cancer, Vol. 79, No. 10, 1997, pp. 1884 1889.
[10] H. Kato, Y. Ichinose, M. Ohta, E. Hata, N. Tsubota, H. Tada, Y. Watanabe, H. Wada, M. Tsuboi, J. Hamajima and M. Ohta, “A Randomized Trial of Adjuvant Chemotherapy with UracilTegafur for Adenocarcinoma of the Lung,” The New England Journal of Medicine, Vol. 350, No. 17, 2004, pp. 17131721.
[11] M. Yamamoto, S. Arii, K. Sugihara and T. Tobe, “Adjuvant Oral Chemotherapy to Prevent Recurrence after Curative Recection for Hepatocellular Carcinoma,” British Journal of Surgery, Vol. 83, No. 3, 1996, pp. 336340.
[12] T. Ishikawa, T. Ichida, Y. Ishimoto, J. Yokoyama, M. Nomoto, Y. Ebe, et al., “Complete Remission of Multiple Hepatocellular Carcinomas Associated with Hepatitis C VirusRelated, Decompensated Liver Cirrhosis by Oral Administration of EntericCoated Tegafur/Uracil,” The American Journal of Gastroenterology, Vol. 94, No. 6, 1999, pp. 16821685.
[13] K. Hasegawa, T. Takayama, M. Ijichi, Y. Matsuyama, H. Imamura, K. Sano, Y. Sugawara, N. Kokudo and M. Makuuchi, “UracilTegafur as an Adjuvant for Hepatocellular Carcinoma: A Randomized Trial,” Hepatology, Vol. 44, No. 4, 2006, pp. 891895.
[14] O. Nakajima, K. Ihara, T. Isoda, Y. Takemasa, Y. Imamura and Y. Koyama, “Phase I and Phase II Studies on a Mixture of 1(2Tetrahydrofulyl)5Fluorouracil and Uracil (UFT),” Japanese Journal of Cancer and Chemotherapy, Vol. 7, 1980, pp. 15581568.
[15] Y. M. Rustum, “MechanismBased Improvement in the Therapeutic Selectivity of 5FU Prodrug Alone and under Conditions of Metabolic Modulation,” Oncology, Vol. 54, No. (Suppl. 1), 1997, pp. 711. A. Lee, H. Ezzeldin, J. Fourie and R. Diasio, “Dihydro pyrimidine Dehydrgenase Deficiency: Impact of Phar macogenetics on 5Fluorouracil Therapy,” Clinical Advances in Hematology and Oncology, Vol. 2, No. 8, 2004, pp. 527532.
[16] H. Baba, K. Teramoto, T. Kawamura, A. Mori, M. Imamura and S. Arii, “Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Activities in Hepatocellular Carcinomas and in Deseased Livers,” Cancer Chemotherapy and Pharmacology, Vol. 52, No. 6, 2003, pp. 469476.
[17] H. Ueda, H. Tanaka, Y. Kida, H. Fukuchi and M. Ichinose, “Adjuvant Chemotherapy with Tegafur/Uracil Administration after Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma,” Oncology Reports, Vol. 19, No. 5, 2008, pp. 13551361.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.